Merck To Pay Up To $425m For Foghorn’s Gene Regulation Therapies

Major Deal For ‘Gene Traffic Control’ Company

 
• By Andrew McConaghie
  
Cambridge
The Cambridge, MA-based firm has been around since 2016, and came out of 'stealth mode' two years ago
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip